warfarin and Hyperparathyroidism

Chronic kidney disease (CKD) patients have a higher risk of cardiovascular (CVD) morbidity and mortality compared to the general population. The links between CKD and CVD are not fully elucidated but encompass both traditional and uremic-related risk factors. The term CKD-mineral and bone disorder (CKD-MBD) indicates a systemic disorder characterized by abnormal levels of calcium, phosphate, PTH and FGF-23, along with vitamin D deficiency, decreased bone mineral density or altered bone turnover and vascular calcification. A growing body of evidence shows that CKD patients can be affected by subclinical vitamin K deficiency; this has led to identifying such a condition as a potential therapeutic target given the specific role of Vitamin K in metabolism of several proteins involved in bone and vascular health. In other words, we can hypothesize that vitamin K deficiency is the common pathogenetic link between impaired bone mineralization and vascular calcification. However, some of the most common approaches to CKD, such as (1) low vitamin K intake due to nutritional restrictions, (2) warfarin treatment, (3) VDRA and calcimimetics, and (4) phosphate binders, may instead have the opposite effects on vitamin K metabolism and storage in CKD patients.

Topics: Calcium; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism; Osteocalcin; Phosphates; Renal Insufficiency, Chronic; Risk Factors; Vascular Calcification; Vitamin K; Vitamin K Deficiency; Warfarin

We report a rapid, sensitive and reproducible method to measure free gamma-carboxyglutamic acid (GLA) in serum using precolumn derivatization with O-phthalaldehyde, reversed-phase chromatography and deproteinization of serum by ultrafiltration. Serum free GLA level in 62 healthy adults was 167 +/- 46 pmol/ml and was increased (302 +/- 195 pmol/ml) in 14 patients with primary hyper-parathyroidism, a disease characterized by an increased bone turnover. Peptide bound GLA averaged 413 pmol/ml. In rabbits receiving massive doses of warfarin during 6 days there was a time- and dose-dependent decrease of serum free GLA but a significant fraction was still measurable. These data indicate that free GLA circulates and originates both from the metabolism of the vitamin K-dependent clotting factors and from bone metabolism.

Topics: 1-Carboxyglutamic Acid; Animals; Bone and Bones; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Hyperparathyroidism; Male; Methods; Peptides; Protein Binding; Rabbits; Vitamin K; Warfarin